RPSG Ventures Ltd
RPSG Ventures Ltd
Commercial ServicesKey Fundamentals
MicrocapBPO / KPOCommercial ServicesInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view RPSG Ventures Ltd insights
28 extracted metrics + investor summaries across FY13–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of -3.18% over last 3 years.
Growth Rate
AI Analysis — Bull vs Bear
RPSG Ventures Ltd is a services conglomerate trading at a market cap of Rs 2,799 crore with a P/B of 1.10x, indicating near book-value pricing. However, the company reports a negative 3-year average ROE of -3.02% and a TTM profit decline of -156%, reflecting significant profitability challenges despite consistent top-line growth of 15-18% over recent periods.
- Stock trades at just 1.10x book value, offering near-asset-value entry for a diversified services conglomerate
- TTM revenue growth of 18% indicates strong top-line momentum and improving business traction
- 3-year compounded sales growth of 16% demonstrates sustained revenue expansion over a meaningful period
- 5-year compounded sales growth of 15% shows the company has consistently scaled its revenue base
- 3-year stock CAGR of 23% shows the market has historically rewarded the company's growth trajectory
- 3-year compounded profit growth of 3% shows the company has at least maintained nominal profitability on a longer timeframe despite recent setbacks
- 5-year stock CAGR of 8% indicates positive long-term wealth creation for shareholders despite recent correction
- TTM compounded profit decline of -156% signals a severe deterioration in earnings, potentially moving from profit to loss
- PE ratio of 1,659.9x is extraordinarily elevated, implying negligible current earnings relative to market cap
- 3-year average ROE of -3.02% indicates the company is destroying shareholder value rather than generating returns on equity
- Last year ROE of -5% shows profitability deterioration is worsening, not improving
- Zero dividend yield despite reporting profits indicates no cash return to shareholders and possible cash flow constraints
- Low interest coverage ratio suggests debt servicing burden is consuming a significant portion of operating earnings
- 5-year compounded profit decline of -20% reveals a structural inability to convert revenue growth into bottom-line gains
- 1-year stock return of -10% reflects recent market skepticism about the company's near-term earnings trajectory
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Acquires Clarionix, merges Woodlands Hospital Jun 25
RPSG Ventures acquired 100% of Clarionix Healthcare for INR 1 lakh and approved a composite scheme to merge Woodlands Hospital, expanding its healthcare footprint.
- New director with 99.99% approval Jun 19
Sudip Kumar Ghosh appointed as Director and Whole-Time Director via postal ballot with over 99.99% shareholder approval, signaling strong governance alignment.
- ICML holds 56.2L shares, no encumbrance Jun 17
Integrated Coal Mining Limited held 56,20,072 shares in RPSG Ventures as of March 31, 2026, with no encumbrance reported during FY26.
- Digidrive holds 3.08L shares unencumbered Jun 12
Digidrive Distributors Limited holds 3,08,997 equity shares in RPSG Ventures as of March 31, 2026, with no pledge or encumbrance during FY26.
- STEL Holdings declares 3.30% stake Jun 9
STEL Holdings Limited disclosed a 3.30% shareholding in RPSG Ventures as of March 31, 2026, confirming no encumbrance was created during FY26.
TL;DR: RPSG Ventures is actively expanding into healthcare through the Clarionix acquisition and Woodlands Hospital merger, while leadership strengthening received near-unanimous shareholder backing. No headwinds are visible in recent news flow and promoter/group entities report clean, unencumbered holdings. The trend is constructive with strategic diversification moves, though execution on healthcare integration remains a forward watch item.
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,792 | 2,296 | 1,788 | 1,846 | 2,020 | 2,516 | 2,166 | 2,385 | 2,541 | 2,971 | 2,668 | 2,756 | 2,927 |
| Expenses | 1,629 | 1,680 | 1,578 | 1,653 | 1,803 | 1,964 | 1,948 | 2,117 | 2,207 | 2,371 | 2,362 | 2,430 | 2,560 |
| Operating Profit | 163 | 616 | 211 | 194 | 217 | 552 | 218 | 268 | 335 | 600 | 306 | 327 | 367 |
| OPM % | 9% | 27% | 12% | 10% | 11% | 22% | 10% | 11% | 13% | 20% | 11% | 12% | 13% |
| Other Income | 11 | 5 | 35 | 18 | 8 | 8 | 16 | 18 | 67 | 18 | 38 | -95 | 74 |
| Interest | 145 | 152 | 152 | 151 | 172 | 169 | 177 | 190 | 200 | 198 | 211 | 213 | 251 |
| Depreciation | 74 | 72 | 76 | 77 | 78 | 83 | 89 | 95 | 103 | 110 | 123 | 124 | 130 |
| PBT | -45 | 398 | 19 | -16 | -24 | 308 | -33 | 1 | 98 | 310 | 10 | -105 | 61 |
| Tax % | 191% | 9% | 181% | 256% | 293% | 12% | 118% | 4284% | 87% | 19% | 497% | 30% | 218% |
| Net Profit | -132 | 362 | -15 | -55 | -95 | 270 | -73 | -46 | 12 | 251 | -41 | -136 | -72 |
| EPS in Rs | -41.69 | 51.84 | -11.72 | -20.7 | -30.16 | 30.8 | -23.53 | -18.13 | -3.96 | 25.11 | -15.72 | -33.71 | -17.38 |
Profit & Loss
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,993 | 4,370 | 4,608 | 5,599 | 6,670 | 7,166 | 7,951 | 9,608 | 11,323 |
| Expenses | 1,776 | 3,981 | 4,204 | 4,895 | 5,781 | 6,361 | 6,694 | 8,222 | 9,716 |
| Operating Profit | 217 | 389 | 405 | 704 | 889 | 806 | 1,257 | 1,386 | 1,607 |
| OPM % | 11% | 9% | 9% | 13% | 13% | 11% | 16% | 14% | 14% |
| Other Income | 12 | 21 | 36 | -53 | 122 | 172 | 48 | 95 | 28 |
| Interest | 28 | 61 | 102 | 107 | 211 | 552 | 627 | 737 | 872 |
| Depreciation | 44 | 95 | 225 | 249 | 291 | 305 | 302 | 370 | 487 |
| PBT | 157 | 254 | 114 | 294 | 508 | 120 | 377 | 374 | 276 |
| Tax % | -4% | 8% | 33% | 80% | 33% | 149% | 48% | 56% | 99% |
| Net Profit | 164 | 235 | 76 | 58 | 339 | -59 | 197 | 164 | 2 |
| EPS in Rs | — | 24.2 | -25.63 | -36.09 | 49.31 | -51.73 | -12.83 | -14.82 | -41.7 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 27 | 27 | 27 | 27 | 30 | 33 | 33 | 33 |
| Reserves | 2,147 | 2,253 | 2,300 | 2,132 | 2,497 | 2,376 | 2,634 | 2,630 | 2,473 |
| Borrowings | 849 | 852 | 1,912 | 1,708 | 2,810 | 3,414 | 4,211 | 6,152 | 8,243 |
| Other Liabilities | 1,680 | 1,913 | 1,946 | 2,315 | 7,266 | 7,093 | 6,821 | 7,133 | 7,969 |
| Total Liabilities | 4,676 | 5,045 | 6,185 | 6,182 | 12,599 | 12,913 | 13,699 | 15,948 | 18,718 |
| Fixed Assets | 2,976 | 3,140 | 3,983 | 4,078 | 9,934 | 9,956 | 10,066 | 11,272 | 12,714 |
| CWIP | 5 | 55 | 7 | 5 | 9 | 7 | 23 | 59 | 65 |
| Investments | 128 | 290 | 94 | 240 | 495 | 439 | 438 | 554 | 753 |
| Other Assets | 1,567 | 1,561 | 2,100 | 1,859 | 2,161 | 2,511 | 3,172 | 4,063 | 5,187 |
| Total Assets | 4,676 | 5,045 | 6,185 | 6,182 | 12,599 | 12,913 | 13,699 | 15,948 | 18,718 |
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating | -35 | 358 | 184 | 901 | 662 | 726 | 1,038 | 1,098 | 1,233 |
| Investing | -180 | -282 | 94 | -458 | -1,453 | -719 | -1,137 | -1,589 | -2,110 |
| Financing | 361 | -102 | -79 | -652 | 855 | 252 | 291 | 754 | 837 |
| Net Cash Flow | 146 | -26 | 199 | -209 | 64 | 259 | 192 | 263 | -40 |
| Free Cash Flow | -75 | 148 | 37 | 719 | -152 | -71 | 217 | 83 | 336 |
| CFO/OP | -2 | 114 | 59 | 137 | 88 | 103 | 89 | 90 | 91 |
Ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73 | 37 | 48 | 40 | 56 | 56 | 62 | 69 | 73 |
| Cash Conversion Cycle | 73 | 37 | 48 | 40 | 56 | 56 | 62 | 69 | 73 |
| Working Capital Days | -50 | -19 | -38 | -33 | -76 | -108 | -107 | -95 | -128 |
| ROCE % | — | 7% | 4% | 9% | 12% | 9% | 12% | 11% | 11% |
Documents
Frequently Asked Questions about RPSG Ventures Ltd
What does RPSG Ventures Ltd do?
Where is RPSG Ventures Ltd (RPSGVENT) listed?
Which sector does RPSG Ventures Ltd belong to?
What is the market capitalisation of RPSG Ventures Ltd?
What is the PE ratio of RPSG Ventures Ltd?
What is the 52-week high and low of RPSG Ventures Ltd?
What is the Return on Equity (ROE) of RPSG Ventures Ltd?
How can I research RPSG Ventures Ltd on Tapetide?
Company Information
RPSG Ventures Ltd owns and operates a diversified portfolio of businesses including information technology (IT) services, business process management (BPM), fast moving consumer goods (FMCG), Ayurveda formulations, real estate, sports and restaurants. All of its businesses are carried out through various subsidiary companies except of its IT services business.[1]